Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026

2026-02-12 05:44:44 ET

Thesis: Preliminary 2025 results indicate continued momentum

Syndax Pharmaceuticals ( SNDX ) recently announced some preliminary FY25 financial results, and I have to say, they do show some decent commercial and operational progress. The main highlights are the successful launches of Revuforj (revumenib) and Niktimvo (axatilimab-csfr) after their respective FDA approvals. We can expect Revuforj to generate about $44 million in 4Q25 net revenue. This would be a pretty notable 38% increase in quarterly revenue compared to what we saw in 3Q25, but keep in mind this boost is partly due to rising prescriptions after the drug’s approval in relapsed/refractory NPM1-mutated AML....

Read the full article on Seeking Alpha

For further details see: